145 related articles for article (PubMed ID: 23454518)
1. Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles.
Trapani A; Di Gioia S; Ditaranto N; Cioffi N; Goycoolea FM; Carbone A; Garcia-Fuentes M; Conese M; Alonso MJ
Int J Pharm; 2013 Apr; 447(1-2):115-23. PubMed ID: 23454518
[TBL] [Abstract][Full Text] [Related]
2. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
3. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma.
Oyarzun-Ampuero FA; Brea J; Loza MI; Torres D; Alonso MJ
Int J Pharm; 2009 Nov; 381(2):122-9. PubMed ID: 19467809
[TBL] [Abstract][Full Text] [Related]
4. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
5. Preparation, optimization, and in-vitro/in-vivo/ex-vivo characterization of chitosan-heparin nanoparticles: drug-induced gelation.
Shahbazi MA; Hamidi M; Mohammadi-Samani S
J Pharm Pharmacol; 2013 Aug; 65(8):1118-33. PubMed ID: 23837580
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
7. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules.
Giovino C; Ayensu I; Tetteh J; Boateng JS
Int J Pharm; 2012 May; 428(1-2):143-51. PubMed ID: 22405987
[TBL] [Abstract][Full Text] [Related]
8. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
[TBL] [Abstract][Full Text] [Related]
9. Facile preparation of well-defined near-monodisperse chitosan/sodium alginate polyelectrolyte complex nanoparticles (CS/SAL NPs) via ionotropic gelification: a suitable technique for drug delivery systems.
Liu P; Zhao X
Biotechnol J; 2013 Jul; 8(7):847-54. PubMed ID: 23625874
[TBL] [Abstract][Full Text] [Related]
10. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system.
Krauland AH; Alonso MJ
Int J Pharm; 2007 Aug; 340(1-2):134-42. PubMed ID: 17459620
[TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
12. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
13. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations.
Al-Qadi S; Grenha A; Carrión-Recio D; Seijo B; Remuñán-López C
J Control Release; 2012 Feb; 157(3):383-90. PubMed ID: 21864592
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Lin A; Liu Y; Huang Y; Sun J; Wu Z; Zhang X; Ping Q
Int J Pharm; 2008 Jul; 359(1-2):247-53. PubMed ID: 18457928
[TBL] [Abstract][Full Text] [Related]
15. Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers.
Hafner A; Lovrić J; Voinovich D; Filipović-Grcić J
Int J Pharm; 2009 Nov; 381(2):205-13. PubMed ID: 19596430
[TBL] [Abstract][Full Text] [Related]
16. Effect of preparation parameters on ultra low molecular weight chitosan/hyaluronic acid nanoparticles.
Nazeri N; Avadi MR; Faramarzi MA; Safarian S; Tavoosidana G; Khoshayand MR; Amani A
Int J Biol Macromol; 2013 Nov; 62():642-6. PubMed ID: 24099942
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.
Makhlof A; Tozuka Y; Takeuchi H
Eur J Pharm Sci; 2011 Apr; 42(5):445-51. PubMed ID: 21182939
[TBL] [Abstract][Full Text] [Related]
18. Foot and Mouth Disease virus-loaded fungal chitosan nanoparticles for intranasal administration: impact of formulation on physicochemical and immunological characteristics.
Tajdini F; Amini MA; Mokarram AR; Taghizadeh M; Azimi SM
Pharm Dev Technol; 2014 May; 19(3):333-41. PubMed ID: 23590209
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release.
Yuan Z; Ye Y; Gao F; Yuan H; Lan M; Lou K; Wang W
Int J Pharm; 2013 Mar; 446(1-2):191-8. PubMed ID: 23422276
[TBL] [Abstract][Full Text] [Related]
20. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.
Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
Int J Pharm; 2013 Oct; 455(1-2):241-7. PubMed ID: 23876499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
